ProQR Therapeutics N.V. logo
ProQR Therapeutics N.V. PRQR
$ 2.46 5.36%

Annual report 2024
added 12-13-2025

report update icon

ProQR Therapeutics N.V. Financial Statements 2011-2025 | PRQR

Annual Financial Statements ProQR Therapeutics N.V.

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- - - 68.7 M 188 M 291 M 454 M 85 M 96.9 M 123 M 223 M - - -

Shares

- - - 64.2 M 41 M 41 M 34.1 M 25.4 M 23.3 M 23.3 M 11.1 M - - -

Historical Prices

1.4 2.38 1.55 1.07 4.57 7.09 13.3 3.35 4.05 4.34 18.8 - - -

Net Income

- - - -61.7 M -46.6 M -56.5 M -36.9 M -43.6 M -39.1 M -20.8 M -12.1 M -3.25 M - -

Gross Profit

- - - - - - - - - - 313 K - - -

Operating Income

- - - -57.2 M -42.4 M -57.4 M -36.3 M -40.5 M -39.6 M -27 M - - - -

Interest Expense

1.08 M 1.2 M - 3.4 M 2.04 M - - - - - - - - -

EBITDA

- - - -57.2 M -42.4 M -57.4 M -36.3 M -40.5 M -38.5 M -26.6 M -16.3 M -3.19 M - -

Operating Expenses

50 M 41.4 M 69.5 M 59.6 M 51.8 M 59.4 M 42.1 M 42 M 39.8 M 27 M 16.5 M - - -

General and Administrative Expenses

- - - 17.4 M 13.7 M 12.9 M 12.5 M 10.8 M 9.48 M 6.84 M 6.51 M 786 K - -

All numbers in EUR currency

Quarterly Income Statement ProQR Therapeutics N.V.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- - - 71.4 M 71.2 M 68.3 M 66.1 M 50.8 M 50.2 M 50.1 M 50 M 49.9 M 47.4 M 38.9 M 38.9 M 38.9 M - 33.4 M 31.9 M - - - 24 M - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

- - - -14.4 M -18.2 M -15.1 M -15.8 M -12.6 M -13.2 M -13.2 M -4.12 M -16.1 M -18.6 M -12.2 M -11.7 M -14.2 M - -5.99 M -7.4 M - - - -11.4 M - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

- - - 1.23 M 239 K 872 K 243 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- - - -16.9 M -17.3 M -14.6 M -13.2 M -12.1 M -11.7 M -10.9 M -3.36 M -16.5 M -17.4 M -13.4 M -11.8 M -14.7 M - -5.92 M -7.67 M - - - -10.2 M - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - - -16.9 M -17.3 M -14.6 M -13.2 M -12.1 M -11.7 M -10.9 M -3.36 M -16.5 M -17.4 M -13.4 M -11.8 M -14.7 M - -5.92 M -7.67 M - - - -10.2 M - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

- - - 18.3 M 17.8 M 15.7 M 13.9 M 12.2 M 11.9 M 11.1 M 12 M 16.7 M 17.8 M 14 M 12.4 M 15.2 M - 8.88 M 8.64 M - - - 10.4 M - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

- - - 4.91 M 5.32 M 4.59 M 4.12 M 3.34 M 3.51 M 2.81 M 3.45 M 3.92 M 3.92 M 2.9 M 2.88 M 3.19 M - 2.58 M 2.65 M - - - 2.89 M - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in EUR currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements ProQR Therapeutics N.V. PRQR
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting ProQR Therapeutics N.V. plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.93 4.78 % $ 818 M canadaCanada
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.2 -1.69 % $ 247 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Aptevo Therapeutics Aptevo Therapeutics
APVO
$ 1.07 -5.75 % $ 295 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 213.33 -3.22 % $ 5 B danmarkDanmark
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.13 -4.96 % $ 7.53 B australiaAustralia
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
BioVie BioVie
BIVI
$ 1.42 -1.85 % $ 2.1 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
BioNTech SE BioNTech SE
BNTX
$ 93.93 -0.93 % $ 27.2 B germanyGermany
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 26.45 4.67 % $ 1.28 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 9.6 0.37 % $ 141 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 0.26 -6.98 % $ 566 M israelIsrael
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 12.98 -7.91 % $ 854 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 548.58 -2.78 % $ 41.6 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.37 2.83 % $ 14.9 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
$ 91.59 1.95 % $ 96.9 B britainBritain
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 27.09 -1.53 % $ 1.74 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 8.97 -0.44 % $ 1.45 B britainBritain
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 11.33 -1.78 % $ 733 M usaUSA
Biogen Biogen
BIIB
$ 175.2 0.63 % $ 25.5 B usaUSA
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 5.07 -5.5 % $ 108 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 87.67 -0.36 % $ 9.05 B usaUSA
ADiTx Therapeutics ADiTx Therapeutics
ADTX
$ 1.43 -36.18 % $ 18.8 K usaUSA
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 3.28 -9.39 % $ 40.1 M usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 24.29 2.84 % $ 2.88 B usaUSA